0%
of patients on EGFR inhibitors develop a papulopustular rash.
Lacouture ME et al. Oncologist 2008; Support Care Cancer 2011.
Oncology dermatology · CTCAE v5.0
Grade cutaneous adverse events with clinical confidence.
Oncoderm is a focused, mobile-first tool for oncology teams to assess dermatologic toxicities, including erythema, scalp rash, pruritus, oral mucositis, and paronychia, and produce CTCAE-aligned grades in under a minute.
Built on the standards your team already uses
CTCAE v5.0 aligned NCI grading taxonomy ICH-GCP informed WHO oral toxicity scale IGA dermatology framework NRS-11 itch scale GDPR compatible HIPAA compatible EU MDR class IIa pathway OAuth 2.0 + JWT AES-256 at rest CTCAE v5.0 aligned NCI grading taxonomy ICH-GCP informed WHO oral toxicity scale IGA dermatology framework NRS-11 itch scale GDPR compatible HIPAA compatible EU MDR class IIa pathway OAuth 2.0 + JWT AES-256 at rest
Why oncoderm exists
Cutaneous toxicity is the most common adverse event in targeted oncology therapy, and the least standardised to grade.
0%
of patients on immune-checkpoint inhibitors report itch or rash within 6 weeks.
Sibaud V. Am J Clin Dermatol 2018.
0.00 κ
inter-rater agreement on CTCAE skin grading between oncologists; fair, not strong.
Atkinson TM et al. JNCI 2016.
0%
of grade-3 dermatologic AEs trigger dose interruption or discontinuation when graded correctly.
Hassel JC et al. Eur J Cancer 2017.
Patients are penalised twice: by the skin toxicity itself and by the dose modifications that follow. Grading needs to be reproducible, photo-anchored, and fast enough to fit into a 7-minute oncology consultation. That is what Oncoderm is for.
What Oncoderm grades
Five clinical signs. One unified grading flow.
Each sign has its own clinical anatomy: photographic in some cases, questionnaire-based in others. Oncoderm hides that complexity behind a single mobile-first interface, and produces a CTCAE-aligned grade in every case.
Erythema
Skin redness, papulopustular rash, and acneiform eruption, the hallmark dermatologic toxicity of EGFR inhibitors.
- Input
- Single standardised photograph
- Output
- CTCAE Grade 1 – 3
- G1 Papules and/or pustules covering <10% BSA
- G2 Papules and/or pustules covering 10–30% BSA; limiting instrumental ADL
- G3 Papules and/or pustules covering >30% BSA; limiting self-care ADL
Oncoderm’s erythema engine analyses tone, contrast and lesion density against a calibrated reference cohort. Output includes a heat-mapped overlay that lets the clinician verify the AI’s region of interest before signing the grade.
Scalp rash
Pustular folliculitis and seborrheic-pattern dermatitis on the scalp; frequent but underreported on standard CTCAE checklists.
- Input
- Three photos: front, top, back
- Output
- Detected / Not detected
- Detected Pustular, follicular or seborrheic features present on ≥1 view
- Not detected No features on any view
Three-angle capture catches lesions that a single dermoscopic shot misses. The model returns per-view confidence so the clinician can re-photograph an uncertain region rather than over- or under-grade.
Pruritus
Itch is the most disabling subjective symptom in cutaneous oncology toxicity, and it has no biomarker.
- Input
- NRS-11 itch + distribution + excoriation + ADL impact
- Output
- CTCAE Grade 1 – 3
- G1 Mild or localized; topical intervention indicated
- G2 Widespread and intermittent; oral intervention indicated; limiting instrumental ADL
- G3 Widespread and constant; limiting self-care ADL or sleep
Four-question structured assessment combining the NRS-11 itch numeric scale with distribution, excoriation severity, and functional impact; collapses into a single CTCAE grade in real time on the device.
Oral mucositis
Stomatitis is the dose-limiting toxicity for many mTOR inhibitors, chemo-radiotherapy regimens and conditioning protocols.
- Input
- Symptom + dietary + functional questionnaire
- Output
- CTCAE Grade 1 – 4
- G1 Asymptomatic or mild symptoms; intervention not indicated
- G2 Moderate pain or ulcer; not interfering with oral intake; modified diet indicated
- G3 Severe pain interfering with oral intake
- G4 Life-threatening; urgent intervention indicated
Mucositis grading is binary in practice; patients either tolerate oral intake or they don’t. Oncoderm walks the clinician through a four-domain questionnaire and produces the CTCAE grade with a one-tap escalation flag for grades 3 – 4.
Paronychia
Inflammation of the periungual tissue, frequent with EGFR inhibitors and taxane regimens; under-detected because it tends to present late in the treatment cycle.
- Input
- Questionnaire (nail-fold finding, intervention, ADL impact)
- Output
- CTCAE Grade 1 – 3
- G1 Nail fold edema or erythema; disruption of the cuticle
- G2 Pustular discharge or nail plate separation; oral intervention indicated; limiting instrumental ADL
- G3 Surgical intervention or IV antibiotics indicated; limiting self-care ADL
Paronychia grades on a three-factor questionnaire (visual finding, intervention level, ADL impact); the final grade is the highest of the three. The assessment is HCP-administered with the patient present, and no image AI is required.
And one more capability
When the lesion does not fit a CTCAE category
Oncoderm also returns a ranked differential diagnosis with risk metrics from a single photograph, to support the clinician in deciding whether to refer or biopsy. This output is diagnostic decision support, not a CTCAE grade.
How it works
Three taps from open to signed grade.
- 01
Open Oncoderm
No login. No app store. A clinician opens the URL on any phone, tablet, or laptop and starts immediately.
- 02
Capture or answer
For erythema and scalp rash, the camera UI guides standardised photographs. For pruritus and mucositis, four short structured questions.
- 03
Sign the grade
A CTCAE grade with rationale, anchored to the input. The clinician can override, attach a note, and export the assessment as a structured record.
Powered by Legit.Health+
The same AI engine used in regulated dermatology workflows.
Oncoderm calls into Legit.Health+, a dermatology AI platform with a portfolio of severity experts, regulatory documentation, and an eight-year track record in clinical settings. You get an oncology-tuned product on top of an infrastructure that already meets the bar.
Learn about Legit.Health- Image analysis
- Severity experts validated against dermatology reference cohorts
- Multi-language
- English · Português at launch; Español and other languages on request
- Audit trail
- Every grade timestamped and exportable as a structured record
- Privacy
- No login required. Images processed and discarded. No PHI persisted by default.
- Compute
- EU-region inference; AES-256 in transit and at rest
- Regulatory
- Designed for EU MDR class IIa pathway; engine compliant with ISO 13485
Capture photo · questionnaire
CTCAE grade G1 to G4 + rationale
Early access
Bring Oncoderm to your oncology team.
We are onboarding a small cohort of oncology centres, dermatology services, and clinical-trial sites. Tell us about your setting and we will get back within two working days.
- For oncology, dermatology, pharma, CRO
- Pilots 4 – 8 weeks, no commercial commitment
- Languages English, Português at launch; Español on request